STAAR Surgical (NASDAQ:STAA) Shares Bought by Defender Capital LLC.

Defender Capital LLC. grew its stake in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 4.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 677,617 shares of the medical instruments supplier's stock after purchasing an additional 28,430 shares during the quarter. STAAR Surgical comprises about 8.4% of Defender Capital LLC.'s portfolio, making the stock its 4th biggest holding. Defender Capital LLC. owned about 1.38% of STAAR Surgical worth $25,173,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. GAMMA Investing LLC increased its holdings in shares of STAAR Surgical by 313.9% during the 1st quarter. GAMMA Investing LLC now owns 1,308 shares of the medical instruments supplier's stock worth $50,000 after acquiring an additional 992 shares during the last quarter. Covestor Ltd grew its holdings in STAAR Surgical by 38.9% in the 1st quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier's stock valued at $103,000 after buying an additional 754 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in STAAR Surgical in the 2nd quarter valued at $129,000. Larson Financial Group LLC acquired a new position in STAAR Surgical in the 2nd quarter valued at $130,000. Finally, nVerses Capital LLC grew its holdings in STAAR Surgical by 78.3% in the 3rd quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier's stock valued at $152,000 after buying an additional 1,800 shares in the last quarter. Institutional investors and hedge funds own 96.70% of the company's stock.

STAAR Surgical Stock Down 0.9 %

Shares of NASDAQ:STAA traded down $0.27 during trading on Tuesday, reaching $30.42. 439,999 shares of the company traded hands, compared to its average volume of 720,378. STAAR Surgical has a 52 week low of $26.66 and a 52 week high of $52.68. The firm has a market capitalization of $1.49 billion, a PE ratio of 98.13 and a beta of 0.59. The company's 50 day moving average is $32.95 and its two-hundred day moving average is $39.67.

STAAR Surgical (NASDAQ:STAA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The medical instruments supplier reported $0.15 earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.09). STAAR Surgical had a return on equity of 5.60% and a net margin of 4.99%. The business had revenue of $99.01 million for the quarter, compared to the consensus estimate of $95.22 million. During the same quarter in the prior year, the company earned $0.23 earnings per share. STAAR Surgical's quarterly revenue was up 7.3% compared to the same quarter last year. As a group, research analysts anticipate that STAAR Surgical will post 0.16 EPS for the current year.

Analysts Set New Price Targets

STAA has been the topic of a number of research reports. BTIG Research upped their price objective on STAAR Surgical from $46.00 to $53.00 and gave the company a "buy" rating in a report on Monday, July 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a report on Thursday, September 19th. Stifel Nicolaus decreased their price objective on STAAR Surgical from $50.00 to $44.00 and set a "buy" rating on the stock in a report on Monday, August 26th. Morgan Stanley lowered STAAR Surgical from an "equal weight" rating to an "underweight" rating and decreased their price objective for the company from $50.00 to $37.00 in a report on Monday, July 15th. Finally, Canaccord Genuity Group cut their target price on STAAR Surgical from $43.00 to $41.00 and set a "hold" rating for the company in a research report on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $45.57.

Insider Buying and Selling

In other news, Director Arthur C. Butcher bought 1,315 shares of the company's stock in a transaction on Monday, August 12th. The stock was purchased at an average cost of $37.99 per share, for a total transaction of $49,956.85. Following the completion of the transaction, the director now owns 4,208 shares of the company's stock, valued at $159,861.92. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 1.00% of the stock is owned by corporate insiders.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.